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Abstract 
BACKGROUND: Borderline personality disorder (BPD) is prevalent among the 
general population (2% ). Treatment of BPD is with the use of psychotherapy and 
pharmacotherapy. The use of psychotherapy for treatment ofBPD has been well-
established, the effectiveness of pharmacotherapy remains less clear. 
OBJECTNES: To evaluate the effectiveness of olanzapine and fluoxetine on 
outcomes (including depression, anxiety, anger/impulsivity/aggression and global 
assessment of functioning) ofBPD patients. SEARCH STRATEGY: Searched 
PubMed for the terms "fluoxetine" and "borderline personality disorder" and 
"olanzapine" and "borderline personality disorder". SELECTION CRITERIA: 
Only included randomized controlled trials in the English language that focused 
primarily on objective as stated above. MAIN RESULTS: Two fluoxetine studies 
included in this review, only one study showed significant improvement in 
depression and anger in BPD patients receiving fluoxetine but this was small 
(approximately 20% ). Both studies showed significant improvement in global 
assessment of functioning (GAF) in fluoxetine groups. Four olanzapine studies 
included in this review, 3 compared olanzapine to placebo and 1 compared 
olanzapine to a mixed olanzapine-fluoxetine combination (OFC) to fluoxetine. In 
2 of the 3 olanzapine studies, there was significant improvement in depression, 
anxiety and GAF, improvements ranged from 21%-39% for depression and 
anxiety. All 3 olanzapine studies show improvement in 
anger/impulsivity/aggression (highest improvement was 49%). In the mixed 
study, OFC and olanzapine group showed significant improvement in depression 
and anger but this improvement was mild. Anxiety and GAFwere not measured in 
the mixed study. CONCLUSIONS: Overall, fluoxetine leads to mild improvement 
in depression, anger and GAF. Olanzapine treatment ofBPD patients leads to 
mild-moderate improvement in depression, anxiety, anger/impulsivity/aggression 
andGAF. 
Introduction 
Borderline personality disorder (BPD) is a chronic psychiatric disorder 
that is characterized by marked impulsivity, instability of mood and interpersonal 
relationships. Patients are said to stand on the border between neurosis and 
psychosis 1. 
Many studies have shown that dialectical behavioral therapy (DBT) is 
effective in improving outcomes for BPD. These outcomes include depression, 
anxiety, interpersonal functioning, social adjustment, global psychopathology and 
self-mutilation2• However, effectiveness of pharmacotherapy remains less clear. 
In order to determine the main pharmacological therapies in use for BPD 
patients, I performed a search using the PubMed database and the terms 
"borderline personality disorder'' and "pharmacotherapy". These terms identified 
51 articles. The majority of the articles included agents in use ranging from 
neuroleptics (typical and atypical), serotonin reuptake inhibitors (SSRis) and 
other antidepressants, mood stabilizers, benzodiazepines and MAOis. My goal 
was to determine which agents were more effective than placebo in improving the 
BPD outcomes, including depression, anxiety, impulsivity/aggression and a 
complete assessment of psychiatric functioning-global assessment of functioning. 
Epidemiology 
The prevalence of BPD is approximately 2% in the general population3. 
About 75% of these are women. BPD occurs in association with other axis 1 
disorders including mood disorders, substance abuse, eating disorders and post-
traumatic stress disorder. Zanarini et al4 conducted a study in 1998 to assess the 
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lifetime occurrence of a full range ofDSM-III-R axis I disorders in a group of 
patients with criteria-defined borderline personality disorder and comparison 
subjects with other personality disorders. They found that of 504 inpatients with 
personality disorders the majority of them had concurrent axis I disorders. In 
particular, of the 379 patients meeting DSM-III-R (Diagnostic and Statistical 
manual of Mental Disorders, 3'd edition revised) criteria for BPD, 1% had 
psychotic disorders, 10% had somatoform disorders, over 80% had anxiety 
disorders and over 90% had mood disorders. They also found that significantly 
more men had substance abuse than women (82% versus 59%) and significantly 
more women then men had eating disorders (62% versus 21 %). Significantly 
more women were likely to have PTSD than men (61% versus 35%t 
Paris has reported that BPD patients have a high rate of suicide when they 
have concomitant alcohol abuse or mood disorders3. The high prevalence of these 
axis I disorders in BPD patients makes it more likely that a large proportion of 
BPD patients will be suicidal. 
Diagnosis 
According to the Diagnostic and Statistical manual of Mental Disorders, 
fourth edition, text revision (DSM-IV-TR) the diagnosis of borderline personality 
disorder can occur in early adulthood when an individual shows at least five of the 
criteria listed below: 
A pervasive pattern of instability of interpersonal relationships, self-image, and 
the affects, and the marked impulsivity beginning by early adulthood and present 
in a variety of contexts, as indicated by five (or more) of the following: 
~-
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Affective symptoms 
-Affective instability due to marked reactivity of mood (e.g., intense episodic 
dysphoria, irritability or anxiety usually lasting a few hours and only rarely more 
than a few days) 
-Inappropriate, intense anger or difficulty controlling anger (e.g., frequent 
displays oftemper, constant anger, recurrent physical fights) 
-Chronic feelings of emptiness 
Impulsive symptoms 
-Recurrent suicidal behavior, gestures or threats, or self-mutilating behavior 
-Impulsivity in at least 2 areas that are potentially self-damaging (e.g. spending, 
sex, substance abuse, reckless driving, binge eating) 
-A pattern of unstable and intense personal relationships characterized by 
alternating between extremes of idealization and devaluation 
Interpersonal symptoms 
-Frantic efforts to avoid real or imagined abandoument 
-Identity disturbance: markedly and persistently unstable self-image or sense of 
self 
Cognitive symptoms 
-Transient, stress-related paranoid ideation or severe dissociative symptoms 
*Paris has grouped the criteria based on the basic trait dimensions (affective, 
impulsive, interpersonal and cognitivef. 
Despite the criteria set forth by the DSM-N for the diagnosis ofBPD, the 
diagnosis is still difficult to make. Paris has addressed a number of factors that 
account for this4• One of these is the wide range of symptoms seen in BPD that 
are typical of other axis 1 disorders including mood and anxiety disorders which 
. may lead BPD patients to be misdiagnosed. Additionally, patients may also have 
concurrent axis 1 disorders in addition to the BPD, leading to their BPD going 
undiagnosed as their axis 1 disorders are being treated5. 
The diagnosis ofBPD therefore relies not only on relying on the DSM-N 
criteria but also a good and long term relationship with a patient such that the 
clinician can recognize the multiplicity and chronicity of symptoms5. Clinicians 
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are often forced to rely on information from family members, friends and other 
health care provides making the diagnosis even more complex5. 
Natural course and prognosis 
The management ofBPD patients is difficult for psychiatrists and other 
physicians because these patients present with chronic suicidality, including 
multiple suicidal threats and attempts over years. What is even more troubling for 
physicians is that about 1 in 10 BPD patients eventually succeed in completing 
suicide5. Predicting which BPD patients will commit suicide is difficult and about 
90% of patients improve despite threatening to complete suicide on multiple 
occasions 5• Moreover, overzealousness on the part of the physician to hospitalize 
BPD patients when they threaten or act suicidal can be counterproductive and 
reverse any progress that had been made6• 
In spite ofthis chronic suicidality, most patients with BPD improve over 
time. Approximately 75% ofBPD patients will have nearly normal functioning by 
the age of 35 to 40 years and 90% will recover by the age of 50. While the 
mechanism of recovery is unclear, it has been shown that with increasing age of 
BPD patients, there is a decrease in impulsivity and an avoidance of stressful 
interpersonal relationships5. 
Treatment 
In his commentary on the American Psychiatric Association Guidelines 
(AP A) for the treatment ofBPD, Paris has commented on the use of both 
psychotherapy and pharmacotherapy6. The mainstay of treatment for BPD 
continues to be psychotherapl. While there has been some use of psychoanalytic 
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therapy in the treatment ofBPD patients, there has been ample evidence for the 
use of dialectical behavior therapy (DBT) particularly in an outpatient setting6• 
DBT draws upon supportive, cognitive and behavioral therapies. It was 
developed by Marsha Linehan who based her theory on the inability ofBPD 
patients to identifY emotional experiences and tolerate frustration or rejection. The 
main functions ofDBT are (1) enhance and expand patient's skillful behavioral 
patterns, (2) improve patient's motivation to change, (3) ensure that the new 
behavioral patterns generalize from the therapeutic to the natural environment (4) 
structure the environment so that effective 
behaviors are reinforced, and (5) to enhance the motivation and capabilities of the 
therapist so that effective treatment is rendered1. DBT includes individual and 
group therapy with homework assignments also forming part of the treatment. 
DBT has been shown to be effective with an improvement in interpersonal 
relationships and decreased parasuicidal behaviors 1. 
The effectiveness ofDBT suggests that what BPD patients benefit most 
from is the development of a practical relationship with another human being. 
Nevertheless, DBT is very resource-intensive, time consuming and expensive. 
There is thus a need to determine if other treatments exist for those who are 
unable to participate in DBT or who need an additional supplement to DBT or for 
those admitted to hospitals who only require treatment for a short time. 
Accordingly, various pharmacotherapies have been suggested in the treatment of 
BPD. When used as an adjunct to DBT, pharmacotherapy may aid in the relief of 
symptomatic distress associated with BPD. For instance, antipsychotics are used 
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to treat cognitive/perceptual symptoms, SSR!s to treat affective dysregulation and 
mood stabilizers for impulse-behavioral dyscontrol6. 
Currently, no algorithms have been established for the pharmacotherapy of 
BPD. In many axis 1 disorders such as depression, algorithms have been useful 
since there is an established effective treatment which allows the clinician to be 
able to modify therapy for treatment-resistant cases. The AP A guidelines have 
been unable to make clear what medications are effective for BPD6. As a result, 
many BPD patients end up receiving multiple medications. A prospective study 
by Zanarini eta! found that 40% of borderline patients were taking 3 or more 
concurrent psychiatric medications over 6 years of follow up, 20% were taking 4 
or more concurrent psychiatric medications and 10% were taking 5 ofmore7• 
There is a need to minimize polypharmacy for BPD patients by 
determining whether particular medications would produce the most benefit. 
Additionally, clarification of the effectiveness of particular medications would 
provide the evidence basis for the use of BPD management algorithms. Finally, 
use of this research would provide an opportunity to use these medications in the 
presence of a stable and effective DBT program in order to have a more 
pronounced effect. 
Given the risk of impulsive medication over -use by this population, I 
decided to limit my findings to those agents that were safe. I excluded 
medications that had a high risk of death from overdose (ex. tricycylic 
antidepressants have high risk of death from overdose), high risk of abuse 
(benzodiazepines), significant side effects (typical neuroleptic haldol), or needed 
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more frequent monitoring (atypical antipsychotic clozapine). I only considered 
those agents that were both safe and that had been tested using randomized 
controlled trials. This left me with two main agents: the atypical antipsychotic 
olanzapine and a selective serotonin reuptake inhibitor (SSRI) fluoxetine. 
I conducted a systematic review to address the following question: Is 
olanzapine or fluoxetine or a combination of the two more effective than placebo 
in improving the outcomes (as measured by depression, anxiety, 
impulsivity/aggression, and a complete assessment of psychiatric functioning-
global assessment of functioning) ofBPD patients? 
Systematic Review of the Literature 
Selection of Articles 
To identify relevant articles, I searched the PubMed database using the 
terms "borderline personality disorder", "olanzapine" and then "borderline 
personality disorder", "fluoxetine". Searches were limited to those in the English 
language. I supplemented these sources by searching the Cochrane Library 
database for the terms "borderline personality disorder" and "treatment". 
All abstracts were reviewed. Articles that did not primarily focus on the 
treatment of borderline personality disorder symptomatology were excluded 
because their focus did not address the question at hand. Bibliographies of articles 
that were not excluded were hand-searched and articles that were relevant to the 
pharmacotherapeutic treatment of borderline personality disorder using 
olanzapine, fluoxetine or both were reviewed. Inclusion of a comparison group 
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was required. Studies that were not double-blinded randomized clinical trials and 
reviews that were nonsystematic were excluded. 
Studies were also limited to those including the diagnosis of BPD based 
on the DSM-N or DSM-ITIR criteria for BPD, or DSM-N or DSM-ill-R and 
Diagnostic Interview for borderlines (DIB-R) criteria for borderline personality 
disorder. Studies had to have outcomes that included depression, anxiety, 
anger/impulsivity or assessment of functioning. 
The search for "borderline personality disorder", "olanzapine" yielded 17 
articles of which 4 articles met inclusion criteria. Whereas, the search for 
"borderline personality disorder", "fluoxetine" yielded 28 articles of which only 2 
articles met inclusion criteria. Table 1 shows the articles that were selected. 
Appraisal of the Randomized controlled trials of the treatment ofBPD patients 
with olanzapine, or fluoxetine, or both 
Internal Validity 
Of the 6 articles selected, their quality was judged according to a 0-3 scale 
checklist (O=poor, 1 =fair, 2=good, 3=excellent) and potential for bias (0 means no 
bias represented by 3, +means low potential for bias rep. by 2, ++higher 
potential for bias rep. by 1, +++highest potential for bias rep. by 0). The 
categories considered included representativeness of study population; potential 
for selection bias, measurement tool-equal, reliable and valid; potential for 
confounders; appropriate analysis; outcome-adequately described with 
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significance. Perfect score would be 18 (a score of3 for each category measured). 
Table 2 shows there results. 
Selection of study population 
Studies were assessed based on whether they selected an appropriate study 
population. Studies that were rated as excellent included a study population that 
met the DSM-N or DSM-III-R criteria for BPD and a study population that was 
more homogenous. The inclusion of a homogenous study population should lead 
to the detection of an effect (even if small) in the treatment group if one exists. 
Of the two fluoxetine studies, the study by Salzman et al received a good 
rating because they only included patients with BPD identified using DSM-N 
criteria. In contrast, the study by Simpson et a! received an excellent rating not 
only because they included study participants with BPD (according to DSM-N 
criteria) but they also tried to only include those BPD patients who had affective 
and impulsivity behavioral components to their condition. This improved the 
homogeneity of the study population 
because of the selection of individuals who would benefit from the intervention 
(fluoxetine). Fluoxetine is expected to improve affective and impulsive 
symptoms. However, some BPD patients also have identity disturbance 
symptoms, which would not improve with fluoxetine8• 
Another criterion that was used in evaluating the appropriateness ofthe 
study population was the drop out rate. Studies with a high drop out rate received 
a lower rating than those with a low drop out rate since high drop outs lead to a 
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decreased ability to detect an effect in the treatment group. Both the flnoxetine 
studies had low drop ont rates, with retention of approximately 80%. The study by 
Salzman eta! included a run-in period that improved compliance in the study with 
81.5% of study participants completing the study. In the Simpson et a! study, 80% 
of the individuals completed the study even though there was no run-in period. 
The low drop out rate in this study is probably because the post-treatment 
assessment was carried out at 10 weeks which was before the end of the study (at 
12 weeks) 8• One of the components of BPD is "frantic efforts to avoid real or 
imagined abandonment". If individuals in the study were aware that the study 
was about to end, they could have engaged in actions to deal with their fear of 
abandonment such as dropping out of the study. 
Unlike the fluoxetine studies, high drop out rate was a major problem in 
two of the olanzapine studies (the 2001 Zanarini & Frankenburg study and 
Bogenschutz & Nurnberg study). All the olanzapine studies used the DSM-N 
criteria to establish a diagnosis ofBPD. There were no attempts made to improve 
homogeneity of the study 
population. The studies by Zanarini, Frankenburg (2001) and Bogenschutz & 
Nurnberg had higher drop out rates than the other two olanzapine studies (the 
2004 Zanarini et a! study and the Soler et a! study) 10• 11 • 12•13 . 
Zanarini, Frankenberg (2001) report on a 6 month trial with 28 women 
with BPD. At the end of the trial only 9 subjects remained. Of the 19 subjects 
initially assigned to olanzapine treatment and the 9 assigned to placebo, only 8 
(42.1 %) remained in the olanzapine group and only 1(11.1 %) remained in the 
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placebo. The primary reason cited for this high rate of discontinuation in both the 
olanzapine and placebo groups was loss to follow up. Other reasons cited 
included side-effects such as perceived weight gain, increase in depression or 
anxiety in the olanzapine group and increased depression in the placebo group10• 
The high drop out rate in this study could account for the lack of improvement on 
all outcome measures in the olanzapine group at the end of the study. 
In the study by Bogenschutz and Nurnberg, there were also high drop our 
rates. Of the 40 BPD patients who initially emolled in the study only 23(57.5%) 
remained at the end of the 12 weeks. Reasons for termination in the olanzapine 
group were loss to follow up (1 0%, N=2), lack of efficacy (1 0%), weight gain 
(10%), sedation (10%) and patient's violation of protocol (10%). In the placebo 
group, reasons for termination were loss to follow up (25%, N=5) and lack of 
efficacy (1 0%) 11 . This high drop out rate could explain the lack of positive 
outcome results in the olanzapine group at end point (12 weeks). 
The study by Zanarini eta! (2004) and that by Soler et al had high 
compliance. The short duration of study (8 weeks) in the Zanarini et al (2004) 
trial may have helped to reduce the drop out rate. Ofthe 45 subjects who began 
the study 42 (93%) remained at the end of the study12• In the Soler eta! study 
there was a 4-week selection phase that ensured that of the 60 patients who began 
the study, 42 subjects (70%) completed the 12 week study13• The low drop out 
rates in these studies accounts for the larger positive effect seen in the olanzapine 
treated group on all the outcome measures that were assessed. 
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Selection Bias 
Among the olanzapine studies, those that had the highest drop out rate had 
the greatest potential for selection bias. In the Zanarini, Frankenburg (2001) study 
analysis was done on treatment-completers (not intent-to-treat basis) and of those 
individuals who completed treatment more patients were lost in the olanzapine-
treated group than the placebo group ( 42.1% remained in olanzapine group versus 
11.1% in placebo group)9• This could have resulted in an overestimation of the 
effect of olanzapine on BPD symptoms. In particular, having only one patient in 
the placebo group at the end of the study precludes a reasonable comparison 
between the olanzapine treated group and the placebo group. 
The study by Bogenschutz and Nurnberg began with 20 patients in the 
olanzapine group and 20 in the placebo group. Analysis was based on treatment-
completers (not intent-to treat basis). At the end of the study, there were more 
patients in the placebo (13) than the olanzapine group (1 0) 11 . The number of 
individuals remaining is nearly similar in both groups and the effect is not as 
profound as the Zanarini, Frankenburg study (2001 ). Nevertheless, this difference 
may have led to an underestimation of the effect of olanzapine on BPD 
symptoms. 
In the 2004 study by Zanarini et a! the shorter duration of the study 
reduced the drop out rate thus reducing selection bias. There were no differences 
between the fluoxetine, olanzapine and combined olanzapine fluoxetine groups 
with regard to psychiatric symptoms (OAS-M and MADRS) at baseline11 . 
However, even though the authors report that there were no demographic 
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differences between the groups there is no information provided with regard to the 
number of individuals in each group ( olanzapine and placebo) based on 
demographic characteristics. 
The study by Soler et a! was the most effective at reducing the potential 
for selection bias among the olanzapine studies. They randomly assigned 
individuals after the selection phase in a 1 :I ratio to receive DBT plus olanzapine 
or DBT plus placebo. Randomization was effective and individuals were similar 
in both groups with regard to age, gender, number ofDBT sessions attended and 
measures of psychiatric illness. They were also similar with regard to medications 
that they took-benzodiazepines and antidepressants. Individuals differed only with 
regard to numbers taking mood stabilizers. 10 individuals in the DBT plus 
o!anzapine group took mood stabilizers and only 5 in the DBT plus placebo group 
were on mood stabilizers13. This may have made the positive effects of the DBT 
plus olanzapine treatment more profound. 
The fluoxetine studies did not have such a high potential for selection bias 
as some of the olanzapine studies. In the study by Salzman eta! there was enough 
demographic information provided to compare the fluoxetine and placebo groups. 
The groups were comparable in terms of age, race, marital status, education (years 
of school), prior psychiatric treatment and psychiatric symptoms (DlB-R). Groups 
differed slightly with regard to the number of women in both groups, with the 
fluoxetine group having I 0 women compared to the 4 in the placebo group9. 
The Simpson eta! study also did a good job at reducing selection bias. 
The fluoxetine and placebo group were comparable in terms of demographic 
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characteristics and psychiatric symptoms (SCID-II symptoms endorsed). In 
addition, in this study they included demographic and psychiatric symptoms 
information on drop outs. There were no profound differences between the 
dropouts and the completers of the study. Completers ofthe study in the 
fluoxetine and placebo groups did have slight differences with regard to marital 
status, ethnicity and age. In the fluoxetine group there were 3 married individuals 
and none in the placebo group, 3 single/never married in the fluoxetine group 
compared to 7 in the placebo. Individuals in the fluoxetine gronp were slightly 
older-mean age of39.79 versus 32.73 in the placebo group. More individuals in 
the placebo group were white (10) compared to the fluoxetine group (6). It is 
unclear whether these demographic differences had any effect on the results. 
Measurements and measurement bias 
All but one of the studies in this review used the DSM-N criteria for the 
diagnosis of BPD in measurement of the exposure. The Salzman et a! study used 
the DSM-III-R criteria for diagnosis ofBPD which are very similar to the DSM-
N. The DSM-III-R criteria differ in the definition of affective symptoms as 
shown below14. 
-Affective instability: marked shifts from baseline mood to depression, irritability, 
or anxiety, usually lasting a few hours and only rarely more than a few days 
-Chronic feelings of emptiness or boredom. 
In addition, the DSM-III-R criteria do not include "Transient, stress-related 
paranoid ideation or severe dissociative symptoms" which is included in the 
DSM-N criteria. 
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Various self-report and observer assessments were used to measure 
outcomes in the studies (see table 1 ). The outcome measures included specific 
measurement of various psychiatric symptoms as well as an overall assessment of 
functioning. The observers used to measure outcomes in all the studies included 
in this review were blinded. 
Both the fluoxetine studies used a combination of subjective and objective 
outcome measures. The reliability ofthe objective measure of global assessment 
of functioning (GAF) in the Simpson et al study is questionable. The GAF was 
calculated using the combined means of the therapist-rated GAF and psychiatrist-
rated GAF. However, these values differed at baseline with the therapist-rated 
GAF showing no difference between the DBT/placebo group and the 
DBT/fluoxetine group. But the psychiatrist-rated GAF was significantly higher 
(approximately 10 points) for those in the fluoxetine group compared to the 
placebo group at baseline. This increase on GAF at baseline may have influenced 
the results such that at the end of the study no significant improvement was found 
in overall assessment of functioning in the DBT/fluoxetine group8. 
Ofthe outcome measures used in the Salzman et al, it would have been 
important to determine the validity and reliability of the PDRS (Personality 
Disorder rating Scale) particularly because it was created in this study to assess 
anger and depression. Nevertheless, the study designers also incorporated other 
subjective and objective measures of anger and depression including the OAS-M, 
POMS and HAM-D, the validity and reliability of which have been shown in 
other studies. 
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Regarding the two fluoxetine studies, the Salzman et a! study utilized 
frequent measurements (weekly throughout the 13 week duration of the study) 
while the Simpson et a! study only used two measurements. This frequent 
monitoring may have made it easier to detect an effect in the fluoxetine group in 
the Salzman et a! study. Whereas, in the Simpson et a! study, less frequent 
measuring made it impossible to detect an effect8• 9. 
In two of the olanzapine studies, the 2001 Zanarini and Frankenburg 
study and the Bogenschutz and Nurnberg study there was a measurement of both 
subjective and objective outcome measures. The other two studies (the 2004 
Zanarini et a! trial and the Soler et a! trial) did not use self-report measures. The 
inclusion of subjective measurements of outcome would have been helpful 
because these are an important component of personality disorder diagnosis and 
prognosis. Not including subjective measures probably led to a reduction in the 
effect observed in the medication groups. 
Three of the olanzapine studies conducted in the United States (the 2001 
Zanarini and Frankenburg, the 2004 Zanarini eta! study and the Bogenschutz and 
Nurnberg study) include an assessment of side effects. This is important because 
the occurrence of side effects affects the recommendation of olanzapine for the 
treatment ofBPD. Additionally, the dose of olanzapine and the timing (from the 
onset of treatment) when these side effects occur is important in this 
recommendation 10• 11 ' 12. 
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Statistical Analysis, confounding 
Analysis in the Simpson eta! study was done on treatrnent-completers 
while that in the Salzman eta! study was done on intent-to-treat basis. Each study 
employed a one-way analysis of variance (ANOVA) on the outcome measures at 
pretreatment and postreatrnent to determine differences between fluoxetine and 
placebo groups. Both studies received a rating of2 (good) for the analysis. The 
study by Simpson et a! received a rating of+ (2=good) for the potential for 
confounding. The study by Salzman et a! received a fair rating because of the 
higher potential for confounding in this studl· 9• 
With regard to the olanzapine studies, only the Soler et a! study 
incorporated intent-to-treat analysis13 . Both the Soler eta! and the Bogenschutz 
and Nurnberg studies used ANOV A and ANCOV A. In the Zanarini studies, the 
2001 study utilized Fischer exact test for categorical variables and Wilcoxon rank 
sum test for continuous variables. Random effects regression was then used to 
assess between-group differences in outcomes. In the 2004 Zanarini et a! study, 
analyses were carried out using the logistic 
regression model for categorical variables and multiple regression for continuous 
variables. Three of the olanzapine studies received a quality rating of++ (1 =fair) 
with regard to potential for confounding. The Soler et a! study received a rating of 
+ (2=good) because of the lower potential for confounding10• 11 • 12• 13 • 
Other Limitations 
Overall these studies included small samples and therefore may not be 
powered enough to detect a larger positive effect of the medication ( olanzapine or 
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fluoxetine) on BPD symptomatology if this exists. Also, a number of studies had 
a high drop out rate, further increasing the risk of bias. These limitations are not 
surprising-the nature and characteristics of BPD patients make it difficult to 
have a trial with a significant number of patients if one excludes individuals with 
axis I disorders, those who receive psychotherapy, and those not on psychiatric 
medications. Also, including these individuals in a trial can sometimes dilute the 
effect of the medication on BPD symptoms or complicate the result15• At the 
same time, these sampling characteristics limiting internal validity actually 
improve external validity-many BPD patients suffer from axis I disorders and 
many patients receive 4-5 psychiatric pharmacological agents with all the side 
effects of these agents15. 
-Fluoxetine Studies 
In the Simpson et a! study they took an important component into account 
-the inclusion ofDBT within the clinical trial. At the end of the study, they found 
that DBT/placebo group did better than the DBT/olanzapine group. This result 
can be explained by the inclusion of therapy in this study overwhelming the effect 
of the medication8• 
Additionally, the authors of this study note that they may have been a bias 
towards medication nonresponders because participants in this study were willing 
to discontinue current medications and risk assignment to placebo. However, it is 
worth mentioning that many of those who dropped out did so because of being 
unable to tolerate a nonmedicated condition8. 
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The study population in the Simpson eta! study consisted of hospitalized 
individuals with axis I disorders. The authors note that even though there were no 
patients with bipolar disorder in this study, there could have been some 
individuals with BPD who had an undetected and subclinical form of bipolar 
disorder. Prescribing these individuals antidepressants could have worsened their 
condition explaining the lack of effect in the DBT/fluoxetine group8. 
In the Salzman eta! study, they also obtained some placebo 
responsiveness in their sample. They thus decided to refine their analyses and 
include a measure of placebo responsiveness. After creating a measure of placebo 
responsiveness they used it as a covariate in a series of repeated measures 
analyses of covariance (ANCOVAs) 9. 
The Salzman et a! study included individuals with mild or moderate BPD 
who were relatively high functioning at baseline. This may have affected their 
results since the only significant differences were those on the POMS anger 
subscale. Perhaps, the inclusion of individuals who were already high functioning 
nullified the effects of fluoxetine9• 
-Olanzapine studies 
In the Soler et a! study, BPD participants were allowed to continue 
treatment with some medications (benzodiazepines, antidepressants, and mood 
stabilizers) that they were on before the trial. However, the doses of the 
medications could not be adjusted while in the trial. Of note, more patients in the 
DBT/olanzapine group were on mood stabilizers (N=IO) compared to those in the 
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DBT/placebo group (N=5). This could have accounted for the positive effect seen 
in the DBT/olanzapine group13 . 
Participants in the Soler et a! study were also allowed to continue the use 
of toxic substances. The authors make no mention of what toxic substances were 
included or the distribution of those taking toxic substances in the 
DBT/olanzapine or DBT/placebo groups. This could have biased the results in 
this study13 . 
Even though allowing study participants to continue their psychiatric 
medication or toxic substances allows for the applicability of these results to 
characteristic individuals with BPD, it nevertheless may influence the results 
within the trial so that in the case of the Soler eta! study the effect of olanzapine 
was actually greater than that seen within the study13 . 
In the Bogenschutz and Nurnberg trial, study participants were allowed to 
continue ongoing psychotherapy provided that this had began more than 3 months 
before randomization. There is no mention of what kind of therapy study 
participants were engaged in. The authors do note that only a few individuals 
within the study were involved in therapy (1 in the olanzapine group and 4 in the 
placebo group). However, there was a high drop out rate in this study. As a result, 
even though only 5 individuals were involved in therapy, they could have affected 
the results through an underestimation of the effect of olanzapine11 • 
In the 2004 trial by Zanarini et a!, they failed to include a placebo group. 
Thus while comparisons can be made between taking olanzapine or fluoxetine or 
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a combination of olanzapine and fluoxetine, nothing can be said about how this 
compares to individuals who are not taking these psychiatric medication 12• 
The duration of the trial in all these studies was short. Study duration 
ranged from 12 to 13 weeks in the fluoxetine studies and 8 weeks to 24 weeks in 
the olanzapine studies8• 9• 10' 11 ' 12' 13. This makes conclusions from these trials 
difficult to apply to BPD patients whose condition is much more chronic. 
Some studies such as the Soler et a! study and the 2004 Zanarini et al 
study included only self-rated assessments of outcome whereas others included 
both self-rated and observer assessments of outcome. Including both self-rated 
and observer assessments increases the validity of the results compared to just 
self-rated assessments or observer assessments because of the characteristics of 
BPD patients including the fear of real or imagined abandonment. 
Outcomes Fluoxetine Studies 
Depression 
The two fluoxetine studies in this review reported depression as an 
outcome but the results were mixed. The Salzman et a! study showed a significant 
decline in a self-reported depression scale (POMS) in the fluoxetine group versus 
the placebo group (see table 1 ). There was no significant decline in observer rated 
scales (HAM-D and PDRS). In the Simpson eta! study, the DBT/placebo group 
showed significant improvement on the BD I scale compared to the 
DBT/fluoxetine group8•9. 
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Anxiety 
The only fluoxetine study that measured anxiety was the Simpson et a! 
study and this result did not show improvement in anxiety. Among the 
DBT/fluoxetine group in the Simpson eta! study, there was no significant 
difference in the STAI compared to the DBT/placebo group8. The Salzman eta! 
study did not measure anxiety. 
Anger, Impulsivity and Aggression 
Both the fluoxetine studies measured anger but the results were mixed. In 
the Salzman eta! study there was a significant decline in POMS and PDRS (self-
reported) anger scales in the fluoxetine group compared to the placebo group as 
shown in table 1. Results of the Simpson eta! trial on the other hand indicate near 
significant improvement in the DBT/placebo group compared to the 
DBT/fluoxetine group on anger measurements8•9 
Assessment of Functioning 
In both the fluoxetine studies there was improvement in functioning. GAS 
scores improved significantly in the Salzman eta! study. There was a significant 
improvement in GAF scores in the Simpson eta! study as can be seen in table 18•9. 
Outcomes Olanzapine and Mixed Studies 
Depression 
In the three studies comparing olanzapine to placebo (Bogenschutz and 
Nurnberg study, 2001 Zanarini and Frankenburg study and the Soler eta! study) 
only 2 showed an improvement in depression 11 • 13 . In the Soler et a! study, the 
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DBT/olanzapine group did significantly better than the DBT/placebo group on the 
observer rated HAM-D at the end of the study period (12 weeks) 13 . In the 
Bogenschutz and Numberg study, the olanzapine group did significantly better 
than the placebo group at 8 weeks on the HAM-D scale, but this benefit was not 
significant at the end of the study (12 weeks) 11 • Unlike the two studies mentioned 
above, the 2001 Zanarini and Frankenburg study did not show significant change 
in SCL-90 depressive symptoms at the end of study period which was 24 weeks10• 
The 2004 Zanarini et al study comparing olanzapine, fluoxetine and a 
combination of olanzapine and fluoxetine (OFC) showed that OFC and 
olanzapine groups did better than the fluoxetine group on observer-rated MADRS 
scale for depression. The olanzapine group also did much better than the 
fluoxetine group on the MADRS scalei2• 
Anxiety 
The three olanzapine studies measured anxiety as one of their outcomes 
(the Soler et a1 study, Bogenschutz and Numberg study and the 2001 Zanarini and 
Frankenburg study). The results were mixed. In the Soler et al study, the 
DBT/olanzapine group did better on the HAM-A compared to the DBT/placebo 
group as shown in table 1. The Bogenschutz and Numberg study showed no 
significant changes in HAM-A scales at end point but significant changes in the 
olanzapine group compared to placebo at 8 weeks II_ The 2001 Zanarini and 
Frankenburg study also showed that symptoms improved in the olanzapine group 
compared to placebo at the end ofthe study on SCL-90 symptoms of anxiety10. 
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The 2004 mixed study by Zanarini eta! did not measure anxiety as one of their 
Anger. Impulsivity, Aggression 
All three olanzapine studies also showed an improvement in anger, 
impulsivity and aggression for BPD patients treated with olanzapine compared to 
placebo. In the Soler eta! study, the DBT/olanzapine group showed a greater 
decrease in impulsivity/aggressive behaviors compared to DBT/placebo group13 . 
In the Bogenschutz and Nurnberg study, there was a significant improvement on 
the AIAQ at 8 weeks but this was not significant at the endpoint as seen in table 1. 
In the 200 I Zanarini and Frankenburg study, there was significant improvement 
in the SCL-90 symptoms of anger/hostility and interpersonal sensitivity10. 
The 2004 mixed study by Zanarini et a! showed that the OFC and 
olanzapine groups showed significant improvement on the OASM compared to 
fluoxetine. No significant difference was found between the OFC and olanzapine 
thi 12 groups on s measure . 
Assessment a[ Functioning 
In the two olanzapine studies (the Soler et a! study and the Bogenschutz 
and Nurnberg study) where assessment of functioning was done, there was an 
improvement in the olanzapine group as seen in table I. In the Soler et a! study, 
the DBT/olanzapine group experienced significant improvement in the CGI 
scale 13 . In the Bogenschutz and Nurnberg study, there was a significant 
improvement in the GAF scores at 4 and 8 weeks but not at endpoint11 . Due to the 
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small number of participants in the 2001 Zanarini and Frankenburg study; there 
was no report on the GAF scores of the study population at endpoint10. 
In the mixed study, there was no assessment of overall functioning at the 
end of the study. The only assessment that was done was at the beginning of the 
study and included the mean GAF at baseline which was found to be at the low 
end of fair. 
Side Effects 
All the olanzapine studies reported a number of side effects associated 
with the olanzapine group. The most common symptom was weight gain in all 3 
olanzapine studies; this was significant10• 11 • 13• The average amount of weight 
gained varied by study- 2.87lbs (2001 Zanarini and Frankenburg study), 8.25 lbs 
(Bogenschutz and Nurnberg study) and 6.03lbs (Soler et a! study. In the 2004 
Zanarini et a! study (mixed study), there was no significant weight gain in the 
olanzapine group compared to the fluoxetine group12. Other side effects that were 
noted included increase in cholesterol levels, sedation and mild akathisia·10•11 •12•13• 
Summarv of Internal Validity 
Both fluoxetine studies received a good quality rating. The quality of the 
olanzapine studies varied from fair to good as shown in table 2. All the studies 
were affected by small sample sizes which diminished the power of the study. The 
Soler eta! study had the largest sample size (60) which, while better than the 
studies with 20 individuals, was still under-powered. Additionally, some of the 
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studies suffered from a high degree of selection bias following tbe unequal drop 
out rates in intervention versus placebo groups particularly in two of the 
olanzapine studies (tbe 2001 Zanarini and Frankenburg study and the 
Bogenschutz and Nurnberg study). 
None of the studies reviewed received an excellent rating on 
measurement. This was because they suffered from measurement bias. In some of 
tbe studies, the reliability and validity of the measurement tool were not assessed. 
Most of tbe studies used self-reports which have been shown to be unreliable. 
However, tbey also included observer rated scales which improved the validity of 
tbe assessment tool used. 
Finally, there was a small potential for confounding in all the studies even 
though they were all randomized studies. It was unclear if randomization was 
done well in all tbe studies and even when done appropriately the high and 
unequal drop out rate in some studies introduced some confounding. 
External V aliditv: generalizability to other BPD patients 
Of the fluoxetine studies that were reviewed, the Simpson et a! study had 
the greatest external validity. In this study, tbey included patients diagnosed with 
BPD and concurrent Axis I disorders. Individuals with BPD are frequently 
susceptible to a spectrum of axis I disorders including affective disorders, anxiety 
disorders, eating disorders and substance abuse disorders16. Excluding these 
individuals from a trial frequently limits the results to a minority of patients. 
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The Simpson et a! study also included DBT for both the fluoxetine and 
placebo groups8• This makes their results generalizable to an external BPD 
population. Zanarini et a! reported in their 2004 study on mental heath service 
utilization that over 80% of the BPD patients in their study population were 
involved in some form ofpsychotherapy7• They also found that about 73% of 
BPD patients continued to use outpatient psychotherapy in a sustained manner 
through their 6 year follow up period7• Developing a study that incorporates 
therapy is an essential component of making the results generalizable since many 
BPD patients are involved in therapy. 
The external validity of the other fluoxetine study (the Salzman eta! 
study) was limited by the inclusion ofBPD patients with only mild to moderate 
symptoms. These results cannot be generalized to all BPD patients, some of 
whom may not be as high functioning as those individuals included in this study. 
Of the olanzapine studies reviewed, the Soler eta! study was most 
generalizable to an external population ofBPD patients. Study participants 
included individuals who were already on psychiatric medications including 
benzodiazepines, antidepressants and mood stabilizers. Doses could not be 
modified while in the study. Additionally, participants could continue the use of 
toxic substances as long as they did not fit dependence criteria. Both the 
olanzapine and placebo groups also had DBT included in their regimen13 . Many 
BPD patients are already on psychiatric medications for their BPD symptoms and 
have a high potential for substance abuse. The inclusion of more characteristic 
BPD patients improves the external validity of this study. However, the results of 
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the Soler et al study are not generalizable to inpatients or individuals with active 
Axis I disorders since these were exclusion criteria in this study. 
Both the 2001 Zanarini and Frankenburg study and 2004 Zanarini et al 
study had limitations with regard to their external validity. Among these 
limitations was the exclusion of individuals with axis I disorders, the exclusion of 
men, the exclusion of any individuals who were on any psychiatric medications or 
who were taking any toxic substances( alcohol or drugs) and the exclusion of 
individuals who were acutely suicidal. 
The Bogenschutz and Nurnberg study was applicable to both men and 
women with BPD since these individuals comprised the study population. 
Additionally, in this study individuals who had already began psychotherapy 3 
months prior to randomization were allowed to continue with this, which 
improves the external validity. 
All the studies above were of short duration from 8-24 weeks. This makes 
it difficult to generalize results to BPD patients who need maintenance as well as 
acute management of their symptoms. Whereas, evidence for the effectiveness of 
maintenance therapy in many axis I disorders such as bipolar is available, similar 
evidence for BPD is lacking from these studies 17. 
Discussion 
There is sufficient data to date that shows the effectiveness ofDBT in the 
treatment ofBPD. Less sufficient data exists for the effectiveness of 
pharmacotherapy. However, the use of pharmacotherapy in the treatment ofBPD 
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is important for a number of reasons. Among them is the treatment of BPD 
patients in an inpatient setting where the stay is short, as well as the complexity of 
BPD symptomatology that may necessitate the use of interventions that can 
provide quick responses, such as pharmacotherapy18. In the case of outpatients, 
both psychotherapy and pharmacotherapy are essential in helping to keep patients 
out of the hospital and functioning we!l18• There is therefore a need to determine 
which pharmacotherapy is best and under what circumstances for BPD treatment. 
The American Psychiatric Association guidelines on the treatment of 
borderline personality disorder highlight the basis for use of pharmacotherapy in 
these patients19. First, medications cannot be used as a cure for borderline 
personality disorder. Pharmacotherapy can only be used to diminish symptoms 
and optimize functioning. Second, pharmacotherapy must target specific aspects 
of patient's behavior. Third, affective dysregulation and impulsive aggression 
requires specific attention because they are risk factors for suicidal behavior, self-
injury and assaultiveness. Fourth, medications must target the neurotransmitter 
basis ofbehavior for both acute and chronic components. Finally, symptoms that 
are similar in both borderline personality disorder and axis I disorders can respond 
similarly to the same medication. 
Fluoxetine in the treatment o(BPD patients 
The American Psychiatric Association (APA) recommendations focus on 
three behavioral dimensions of BPD patients. These include affective 
dysregulation, impulsive-behavioral dyscontrol and cognitive-perceptual 
difficulties. These recommendations focus on the availability of evidence to 
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determine the strength of medications in dealing with these behavioral 
dimensions. The medications considered include antidepressants, consisting of 
SSRis ( fluoxetine or sertraline) and serotonin reuptake-norepinephrine reuptake 
inhibitors (SNRis; specifically, venlafaxine) and monoamine oxidase inhibitors 
(MAOis ); mood stabilizers; benzodiazepines; and neuroleptics. While there is no 
mention of atypical antipsychotics such as olanzapine in these 2001 
recommendations19, the olanzapine studies identified were all published following 
the AP A recommendations. 
The AP A recommendations focus on the use of SSRis for the initial 
treatment of affective dysregulation symptoms (including mood lability, rejection 
sensitivity, inappropriate intense anger, depressive "mood crashes" and temper 
outbursts) and impulsive-behavioral dyscontrol symptoms19. The results from the 
two fluoxetine studies in my review contradict this recommendation particularly 
with regard to depression and anger. The Simpson et a! study did not show any 
improvement on measures of anger and depression in the fluoxetine treated group. 
The Salzman et a! study showed improvement in depression and anger. However, 
even on the most rigorous distinguishing score-the POMS anger and depression 
rating-this improvement was small (not more than 20%) and may not be 
clinically significant. The lack of clinically significant improvement on anger and 
depression may be related to the low dose of fluoxetine used in the Salzman eta! 
study (mean 40mg/day) compared to the doses as high as 60-80mg/day in the 
trials considered by the AP A9. 
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According to the AP A, not all BPD patients will respond to fluoxetine and 
it is recommended that a patient be switched from one SSRl to another if the 
response is suboptimal19• A reasonable trial (at least 12 weeks) of the initial SSRl 
must be attempted before switching to another one. lndividuals included in the 
Salzman et a! study may have been unable to respond to fluoxetine and could 
have had a better response with another SSRl. 
The Simpson et a! study (only fluoxetine study to assess anxiety) did not 
show an improvement in anxiety for BPD patients treated with fluoxetine8. This is 
consistent with the AP A guidelines that call for the use ofbenzodiazepines since 
SSRls may not be sufficient at controlling anxiety19. 
The AP A evaluated other antidepressants such as MAO Is and tricyclic 
antidepressants that have been used to treat BPD patients. However, there isn't 
enough evidence to establish their effectiveness in a similar fashion to SSRls. 
Additionally, the use of these other substances is problematic because of the side 
effects associated with them. SSRls are associated with greater treatment 
adherence compared to MAO Is and tricyclic antidepressants because of their 
favorable side effect profile19. Furthermore, MAO Is and tricyclic antidepressants 
are much more lethal in overdose than SSRls. 
ln one study evaluating the effectiveness of amitriptyline and haloperidol 
in the treatment ofBPD patients, the authors reported an increase in suicidal 
ideation, paranoid thinking and assaultiveness in patients receiving 
arnitryptyline20. This is particularly problematic in BPD patients who suffer from 
chronic suicidality and whose course is frequently marked by repeated suicide 
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attempts. Not increasing these patients risk of suicidality is fundamental to an 
effective treatment regimen. 
Olanzapine in the treatment o(BPD patients 
In a systematic review by Grootens and V erkes to evaluate the 
effectiveness of atypical antipsychotics in the treatment ofBPD patients, 4 
antipsychotics were studied: clozapine, risperidone, quetiapine and olanzapine21 . 
When the study by Grooken and Yerkes was published, they only made mention 
of two placebo controlled trials evaluating the effects of olanzapine on outcomes 
for BPD patients. Both those studies were included in my review. 
Much of the work that has been done on the use of pharmacotherapy for 
BPD has dealt with the serotonin pathway. The serotonin pathway is linked to the L 
use oftreatment ofBPD symptomatology using antidepressants. Recently, the 
focus has changed to dealing with dopamine dysfunction and the subsequent use 
of atypical antipsychotics such as olanzapine. Friedel has postulated that 
dopamine dysfunction in BPD patients is linked to impulsivity, emotional 
dysregulation and cognitive-perceptual impairemenr1. Therefore using atypical 
antipsychotics would allow for improvement in these behaviors. 
Compared with classical antipsychotics such as haloperidol and other 
atypical antipsychotic such as clozapine, olanzapine is associated with fewer side 
effects. Frankenburg and Zanarini reported that clozapine (an atypical 
antipsychotic) was effective in reducing symptoms in refractory BPD patients23 • 
However, the use of clozapine is problematic because of the need to monitor 
white blood cell counts23 • In the studies in this review the most significant side 
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effect for BPD patients on olanzapine was weight gain. Other side effects 
included high cholesterol, akathisia and sedation. 
Overall, olanzapine studies suggest mild-moderate improvement in 
depression, anxiety, anger, impulsivity and aggression. The 2001 Zanarini study 
showed an improvement of33.6% on SCL-90 anxiety scores within the first 4 
weeks of the study which then became gradual ( abont 21%) over the remaining 5 
months of the study10. The Soler et a! study, which had the highest improvements 
in outcome, had only moderately significant results at best (39% improvement on 
the HAM-D, 31.3% on the HAM-A and 49.3% on behavioral reports of 
impulsivity and aggression) 13 . 
The dose of olanzapine used in these studies was 2.5 to 20 mg/day with 
study duration ranging from 8-24 weeks10' 11 ' 12' 13. There is a need to incorporate 
the results from these studies in APA guidelines for the treatment ofBPD. 
Additionally, more work is needed with larger samples and over a longer period 
of time to establish the effectiveness of olanzapine in BPD treatment and to better 
appreciate the balance between benefits and costs. 
Mixed Fluoxetine-Olanzapine combination in BPD patients 
The mixed OFC group and olanzapine group produced greater 
improvement in depression, anger, impulsivity and aggression than the fluoxetine 
group. There is no benefit to using a combination of OFC compared to olanzapine 
from this study. Given the greater risk of side effects and costs with medication 
combination, these results suggest using only olanzapine. The improvements in 
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the olanzapine only group were clinically significant with 72.5% improvement on 
MADRS (depression) and 70.8% on OAS-M (aggression) 13. 
This study did not include a placebo group, which would have been 
beneficial in order to make a more accurate comparison of their results. 
Additionally, more studies utilizing fluoxetine, olanzapine, OFC combination and 
placebo are needed together with DBT in all these groups to make results 
generalizable to a BPD population. 
Directions for fUture research 
In all the studies evaluated in this review there is great heterogeneity in 
study populations. Even though the primary focus is on BPD patients, some 
studies included patients with axis I disorders where others excluded these 
patients. Some studies allowed the study population to continue with their 
psychiatric medication or toxic substances where others did not. While this makes 
it difficult to compare the studies, it also points to the dramatic differences that 
exist between BPD patients seen in clinical practice21 • 
Another problem with some of the studies included in this review is the 
high drop out rate. Even where drop out was not high, the size of the study 
population was small. There is a need for larger studies and long term follow-up 
ofBPD patients in these trials. 
Measurement tools that are used to understand the effectiveness of 
medications in the treatment ofBPD need to be similar between studies. Trying to 
answer the question of effectiveness using different measurement tools makes 
comparison of studies difficult. Even when the outcome is the same e.g. 
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depression, the use of the same measurement tool between studies would make 
. . 
compansons easier. 
Comparing the effectiveness of different medications on one outcome 
measure in BPD patients is necessary to avoid polypharmacy ofBPD patients. 
This does not mean that BPD patients cannot be on more than one medication to 
control symptoms. In fact various components ofBPD symptomatology respond 
to different classes of medications. What is important is that current 
recommendations and practices incorporate evidence-based medicine. 
It is important to establish the efficacy of trials for pharmacotherapy in 
BPD patients. One way in which this can occur is by including some component 
of psychotherapy such as dialectical behavioral therapy in outpatient medication 
trials of BPD patients. Doing so will allow these results to be generalizable to 
more BPD patients, many of whom are currently receiving outpatient 
psychotherapy. 
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Table 1: Selected double-blinded, randomized-controlled trials for treatment of BPD using olanzapine, 
fluoxetine or both. 
Study No Source Study Interventions Outcome Measurement &Significant 
Authors, Population Population Results 
Year. 
Salzman, 27 Community 27 mild to moderately Fluoxetine; initial Measurements: 
Wolfson, individuals with symptomatic dose was 20g -Evaluation by independent observers using Hamilton 
Schatzberg, diagnosis of volunteers with capsule, or Rating Scale for Depression (HAM-D), Global 
Looper, BPD. diagnosis of BPD. identical placebo, Assessment Scale (GAS) & Personality Disorder 
Henke, Volunteers Sex-8 men, 14 and then doses rating Scale (PDRS). 
Albanese, women titrated up to a -Self-rated symptoms were assessed by use of the 
Schwartz & Age-mean 36y. max. of 60mgl Profile of Mood States (POMS) and the Mclean 
Miyawaki, Exclusions: Inpatient, day as needed. Hospital Overt Aggression Symptom Checklist(OAS-R) 
1995. hlo psychiatric Results: 
hospitalization, recent -All subjects showed some improvement-50% on PROS, 
suicidal behavior, 20% on POMS & 80% on HAM-D after using 
concurrent secondary contingency table analyses. 
Axis II disorder, self- -Improvement in anger & depression in POMS for 
mutilating behavior fiuoxetine group compared to placebo (p<0.0001) 
(during past 4 years), -GAS scores over time for fiuoxetine group vs. placebo 
major depression or group were significant (p;Q.02) 
Axis I disorder, 
present h/o 
substance abuse, use 
of psychotropic 
medication. 
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Simpson, 25 Admitted 20 women admitted All subjects Measurements: 
Yen, Costello, women to the to the Women's received -Assessment battery administered prior to treatment and 
Rosen, Begin, Women's Partial Program, individual and at week 10. 
Pistorello and Partial recruited using a brief group DBT. Included self-report instruments: Beck Depression 
Pearlstein, Program, a 5- self-report Fluoxetine (or Inventory (BDI), State-Trait Anxiety Inventory (STAI), 
2004. day DBT- questionnaire. placebo) was Overt Aggression Scale 
based partial Sex-20 women, 0 began at -Modified (OAS-M), Dissociative Experiences Scale 
hospital men 20mg/day and (DES), and the State-Trait Anger Expression Inventory 
program. Mean age-34.84 dose advanced (STAXI). A Global Assessment of Functioning scale 
Participants also had to max. (GAF) was also administered. 
to meet 1 borderline anticipated dose 
personality disorder of 40mg/day. Results: 
criterion pertaining to -No significant differences in scores from pre to 
affective instability post-treatment on all measures. 
(e.g. lability or anger) -Within the DBT/placebo group, significant 
& 1 pertaining to pre/posttreatment differences in BDI (p<0.001) and GAF 
impulsivity. (p<0.001) 
Exclusions: primary -No significant differences pre/posttreatment found 
diagnosis of Between DBT!fluoxetine group 
substance 
dependence, a 
seizure disorder, 
unstable medical 
conditions, a lifetime 
history of 
schizophrenia or 
bipolar disorder, 
monoamine oxidase 
inhibitor treatment in 
the prior 2 weeks or a 
previous adequate 
trial of fluoxetine: 
women who were 
pregnant, lactating or 
unwilling to use 
effective birth control. 
----
Zanarini, 2 Women Women Half a tablet per day of study Measurements: 
Frankenb 8 between between the medication (each tablet contained -Self-report measures-Symptom Checklist-90(SCL-90), 
urg, 2001 the ages ages of 18 &40 either 2.5mg of olanzapine or 
-
the Hamilton Depression Inventory (HDI), Dissociatives 
of18to40 with diagnosis matching placebo) at the start of Experiences Scale (DES). 
disturbed of BPD (per the study. Dose was adjusted -Observer rated scales- the Positive and Negative 
by DSM-IV according to perceived response & Syndrome Scale (PANSS), Global Assessment of 
~111o~dines criteria) who side-effects. Functioning scale (GAF). 
---
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s, answered Results: 
distrustful advertisements -Oianzapine vs. placebo group experienced more change 
ness, in Boston area on all the SCL-90 scales except depression. 
impulsivity newspapers On the SCL~90 anxiety scale improvement was 
, painful & relating to significant (p=0.002). 
difficult whether they -Due to small numbers of subjects, results of secondary 
relationshi were disturbed Outcome measures (HOI, DES, PANSS & GAF) not 
ps by moodiness, reported 
recruited distrustfulness, -More side effects were experienced by the olanzapine 
through impulsivity, than the Placebo group including minor sedation 
advertise painful & (Fisher exact test=0.704), constipation (Fisher exact test 
ments in difficult =0.072), weight gain (Fisher exact test=0.026) 
Boston relationships. 
area Mean age-
newspape 26.7y 
rs. Sex-28 
Volunteers women, 0 men 
Exclusions: h/o 
treatment with 
olanzapine, 
medically ill, 
seizure 
disorder, 
currently being 
prescribed any 
psychotropic 
medication that 
they though 
was helping to 
alleviate 
troublesome 
symptoms, 
were actively 
abusing 
alcohol or 
drugs, or were 
acutely suicidal 
(i.e. had a 
clear-cut & 
pressing intent 
to commit 
suicide in the 
near future); 
those who 
were preqnant, 
------
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breastfeeding, 
planning to 
become 
pregnant or not 
using reliable 
forms of 
contraception. 
Zanarini, 4 Women 45 women 2 capsules at beginning of study. Measurements: 
Frankenb 5 aged 18 to meeting Fluoxetine group, 1 capsule Observer-rated measures were Montgomery-Asberg 
urg, 40 years criteria for BPD contained 1 Omg of fluoxetine & Depression rating Scale (MADRS), 
Parachini disturbed from source other capsule contained placebo. Modified Overt Aggression Scale (OAS-M). 
'2004 by population. Olanzapine group, 1 capsule 
moodines SexA5 women contained 2.5mg of olanzapine & Results: 
s, Exclusions: the other contained placebo. -OFC group showed greater improvement over time than 
distrustful Successful Olanzapine-fluoxetine (OFC) fluoxetine on MADRS and OAS-M (p=0.017 & p<0.001 ). 
ness, treatment with group, 1 capsule containing 1 Omg -Oianzapine group showed greater improvement than 
impulsivity fluoxetine or of fluoxetine and the other fluoxetine group on both outcome measures 
, painful & olanzapine, contained 2.5mg of olanzapine. (p<0.0001 and p=0.0033). 
difficult medically ill, -Those in the olanzapine group experienced more mild 
relationshi seizure sedation than those in the fluoxetine or the OFC group 
ps disorder, (p=O. 0064). 
recruited currently -Mild akathisia and weight gain were equally likely among 
through prescribed any all three groups. 
advertise psychotropic 
ments in medication, 
Boston, actively 
Mass. abusing 
area alcohol or 
newspape drugs, acutely 
rs. suicidal (i.e. 
Inclusion had a clear-cut 
criteria: and pressing 
Met DSM- intent to 
IV criteria commit suicide 
for BPD in the near 
using future). Also 
borderline excluded were 
module of those who 
the were pregnant, 
Diagnostic breastfeeding, 
Interview planning to 
for DSM- become 
IV pregnant, or 
Personal it not using 
y reliable forms 
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Disorders of 
(DIPD-IV). contraception 
were also 
excluded. 
Bogensc 4 Patients Medically Study medication started at Measurements: 
hutz, 0 with BPD stable women 2.5mglday (of olanzapine or -9 DSM-IV BPD criteria each scored on a 1-to-7 Likert 
Numberg, recruited and men placebo). Dose increased by 2.5- scale analogous to the Clinical Global Impressions scale 
2004. from the between the 5mg increments/wk. up to modified for borderline personality disorder (CGI-BPD). 
communit ages of 18 and 1 Omglday based on clinical -Standard CGI as secondary global outcome measure. 
y and 60 years with efficacy. After 8 wks, if needed, -Impulsive aggression measure using the Overt 
outpatient diagnosis of dose could be increased by 2.5- Aggression Scale modified (OAS-M) and the Anger, 
clinics at a BPD, recruited 5mg increments/wk. to max. dose Irritability, and Assault Questionnaire (AIAQ). 
university from the of 20mglday. -Depression and anger measured using the Hamilton 
psychiatric community & If intolerable side effects, dose Rating Scale for Depression (HAM-D)and the Hamilton 
hospital. outpatient could be decreased in 2.5-5mg Rating Scale for Anger (HAM-A). 
clinics at a increments/ week. -SCL-90 as secondary self-report measure covering 
university multiple domains of psychopathology. 
psychiatric -Alcohol & drug use measured using Addiction Severity 
hospital. Index (AS I) completed monthly 
Participants -Movement disorders assessed using Abnormal 
required to be Involuntary Movement Scale (AIMS), Barnes Akathisia 
free of mood Scale & Simpson-Angus Scale. 
stabilizers, Results: 
antipsychotics, -Oianzapine found to be superior to placebo on the 
benzodiazepin CGI-BPD at endpoint (p<0.05) 
es and -On the secondary global measure (single item Global 
antidepressant Clinical Impressions scale) results were significant in 
s for at least 2 the olanzapine group compared to the placebo group. 
weeks. -At 8 wks, significant improvement on HAM-D, HAM-A 
Women of andAIAQ 
childbearing -Weight gain significantly greater in olanzapine group 
potential were than placebo group (p=0.027) 
required to 
employ 
effective 
contraception. 
Sex-25women 
& 15 men 
Exclusion: 
Those meeting 
criteria for 
schizophrenia, 
schizoaffective 
disorder, 
bipolar 
'"'"~'~fflll1~'"'"''"1'1'f"111'1'1'''1" ' .,._"' I''"' 
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affective 
disorder, 
current major 
depressive 
episode, 
psychotic 
disorder due to 
substance or a 
general 
medical 
condition, or 
substance 
dependence 
that was not in 
full or partial 
remission. 
Those who 
were actively 
suicidal (i.e. 
any clinically 
significant 
suicidal 
attempts in 
past 6 months 
or any current 
suicidal intent 
or definite 
plan, not 
included were 
self-injurious 
behavior with 
minimal 
potential for 
serious harm 
ex. Superficial 
cutting or 
burning), 
pregnant, had 
significant 
neurological 
impairment. 
Soler, 6 Patients 60 subjects Participants randomly assigned to Measurement: 
Pasual, 0 referred referred from receive dialectical behavior therapy -Clinical scales including Hamilton Depression rating 
Campins, from clinical plus olanzapine or dialectical Scale for affective symptoms, Hamilton Anxiety Rating 
Barrachin clinical services who behavior therapy plus placebo in a Scale for anxiety symptoms, Clinical Global Impression 
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a, services. met inclusion 1:1 ratio. Treatment dose for (CGI) severity of illness scale to evaluate overall performance. 
Puigdem Inclusion criteria and olanzapine was flexible ranging -Biweekly behavioral reports on subject's most dysfunctional 
ont, criteria- who completed from 5 to 20mg/day. behaviors: episodes of impulsivity/aggressive behavior, 
Alvarez, meeting selection self-injuring behavior/ suicide attempts, visits to 
Perez, DSM-IV phase. psychiatric emergency services. 
2005. diagnostic Mean age- Results: 
criteria for 26.95y Analysis done on an intention to treat basis. 
BPDas Sex-52 -DBT & olanzapine group showed grater reduction in 
assessed women, 8 men Depressive symptoms according to Hamilton depression 
by the scale scores compared to the DBT& placebo group 
Structured (p;0.004). 
Clinical -Significant decrease in clinical anxiety according to the 
Interview Hamilton Anxiety rating Score for the olanzapine treated 
for DSM- group compared with placebo (p<0.02). 
IV Axis II -Greater decrease in impulsivity/aggression in the 
Disorders olanzapine group compared to the placebo group 
and the (p;Q.03) 
Revised -Self-injuring behavior/suicide attempts decreased in 
Diagnostic olanzapine group but this was not significant (p;0.08) 
Interview -Significant improvement in CGI in DBT/olanzapine 
for compared to DBT/placebo group. 
Borderline -Oianzapine group experienced significantly more weight 
s: age of gain than placebo patients (p<0.05) 
18-45 -Olanzapine group experienced a significant increase in 
years; Cholesterol levels ( p<0.04) 
Clinical 
Global 
lmpressio 
n (CGI) 
severity of 
illness 
score 
more than 
or equal to 
4; not 
receiving 
psychothe 
rapy; for 
female 
subjects, 
using 
medically 
accepted 
contracept 
ion. 
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Table 2: Quality ratings for randomized controlled trials included in systematic review. Ratings on a scale of 0-3 
or o to +++ for bias (with o representing 3 and +++ representing 0) 
(!)Randomized controlled trials with fluoxetine 
Study Study Potential Measurement Potential for Analysis Outcome Overall 
Authors, Population for Tool-equal, confounders reported Quality 
Year selection reliable, adequately 
Bias valid 
Salzman, 2 ++(1) 2 ++(1) 2 3 11 
Wolfson, 
Schatzberg, 
Looper, Henke, 
Albanese, 
Schwartz and 
Miyawaki, 1995 
Simpson, Yen, 3 +(2) 1 +(2) 2 3 13 
Costello, Rosen, 
Begin, Pistorello 
and Pearlstein, 
2004. 
(II)Randomized lied trials with ol 
------ ------ ------- .. ---- --------· -~--
Study Study Potential Measurement Potential for Analysis Outcome Overall 
Authors, Population for Tool confounders Quality 
Year selection 
Bias 
Zanarini, 2 2 ++(1) 2 2 9 
Frankenburg, +++(0) 
2001 
Zanarini, 2 ++(1) 1 ++(1) 2 3 10 
Frankenburg, 
Parachini, 2004 
Bogenschutz, 2 1 ++(1) 2 2 8 
Numberq, 2004 +++(0) 
Soler, Pasual, 2 +(2) 1 +(2) 2 3 12 
Cam pins, 
Barrachina, 
Puigdemont 
Alvarez, Perez, 
2005 
